Today there is a massive $13.6 billion neurostimulation devices market developing for the ongoing study of the vast arrays of the brain’s neural connections. (1) The diagnostic electrode technology currently used to detect neurological disorders is the same that was developed way back in the 1960s. (2) This is where NeuroOne Medical Technologies (NASDAQ:NMTC) comes into play.
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders that may improve patient outcomes and reduce procedural costs.
Mayo Clinic began testing NeuroOne’s technology in preclinical models and clinical research in 2015 and is presently a top shareholder. (3) NeuroOne Evo electrode product line is complementary to Zimmer Biomet’s ROSA ONE Brain platform used in minimally invasive neurosurgeries. (3) NeuroOne has received FDA approval for their Evo Cortical and sEEG Electrodes. (4) This innovative company is behind the scenes bringing what once could be considered science-fiction-inspired technologies to the brink of creation or they already have it in development. And thanks to NeuroOne’s strategic partnerships they expect their technologies to be widely adopted in the near future. Click HERE to read more about why The Future of Neuroscience is Built on This Thin Film Electrode Technology
Other companies in NeuroOne Medical Tech’s space includes: ENDRA Life Sciences (NASDAQ:NDRA), Second Sight Medical (NASDAQ:EYES), Bluejay Diagnostics (NASDAQ:BJDX), Motus GI Hldgs (NASDAQ:MOTS) and Tivic Health Systems (NASDAQ:TIVC). It could be interesting to research if Tesla’s (NASDAQ:TSLA) co-founder Elon Musk’s company Neuralink and NeuroOne Medical Technologies (NASDAQ:NMTC) have anything in common. As always conduct your own due diligence.
Source 1: https://www.gminsights.com/pressrelease/neurostimulation-devices-market-size
Source 2: https://n1mtc.com/investorsSource
Source 3: https://seekingalpha.com/article/4470806-neuroone-nmtc-stock-thin-film-electrodes-neurological-conditions
Source 4: https://www.mpo-mag.com/contents/view_breaking-news/2021-12-08/fda-clears-neuroone-medical-technologies-evo-seeg-electrode/
Disclaimers: WallStreetPR is simply distributing content provided to us by Bullzeyemedia LLC and is not responsible for the production of this content. WallStreetPR is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are commercial advertisements and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by BullzeyeMedia LLC is not intended to be, nor does it constitute investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report, and publication. In no event shall WALLSTREETPR be liable to any member, guest, or third party for any damages of any kind arising out of the use of any content or other material published or made available by WALLSTREETPR ., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. WallStreetPR.com strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, Wallstreetpr.com, its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. As part of that content, readers, subscribers, and website viewers are expected to read the full disclaimers and financial disclosures statement that can be found on our website by visiting WallStreetPR.com/Disclaimer. WallStreetPR.com has been compensated $750 for advertisement services on NMTC by a 3rd party BullzeyeMedia LLC. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quotes; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.